<DOC>
	<DOCNO>NCT00003116</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : This phase II trial study well give busulfan , cyclophosphamide , filgrastim together peripheral stem cell transplantation sibling donor work treat patient hematologic cancer .</brief_summary>
	<brief_title>High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety feasibility use allogeneic peripheral blood progenitor cell infusion obtain normal histocompatible sibling donor reconstitute bone marrow immunologic function give high-dose busulfan/cyclophosphamide patient hematologic malignancy . - Determine efficacy treatment patient . - Determine ability mobilize hematopoietic progenitor cell normal donor give filgrastim ( G-CSF ) determine hematopoietic progenitor cell content allogeneic peripheral blood progenitor cell collection . - Determine incidence engraftment failure patient . - Determine incidence severe acute graft-versus-host disease patient . OUTLINE : Patients receive high-dose oral busulfan every 6 hour day -8 -5 , cyclophosphamide IV twice day day -4 -3 , cyclosporine IV 6 hour day -1 10 hour day 0 2 dos ( allogeneic ) . Allogeneic peripheral blood progenitor cell IV administer day 0 . Filgrastim ( G-CSF ) administer subcutaneously twice day begin 3 hour completion cell infusion continue blood count recover . Patients follow every month 2 month , every 3 month 6 month , every 6 month disease progression . PROJECTED ACCRUAL : A total 40 patient accrued 15 month period .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically diagnose : Acute myeloid leukemia first , second , third complete remission first second early relapse Acute lymphoblastic leukemia first , second , third complete remission first second early relapse Hodgkin 's lymphoma second third remission first , second , third relapse , refractory NonHodgkin 's lymphoma second third remission first , second , third relapse , refractory Multiple myeloma plasma cell leukemia second third remission first , second , third relapse , refractory Myelodysplastic syndrome deem suitable allogeneic bone marrow transplantation No symptom sign CNS involvement CNS disease free lumbar puncture brain CT scan No active meningeal cancer PATIENT CHARACTERISTICS : Age : 4 55 ( 4 60 donor identical twin ) Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : SGOT/SGPT le 3 time normal Bilirubin le 2.0 mg/dL Renal : Creatinine le 2.1 mg/dL Creatinine clearance least 60 mL/min ( great 1.5 time normal child 40 kg ) Cardiovascular : No uncontrolled hypertension No uncontrolled congestive heart failure No active angina pectoris require nitrate At least 6 month since prior myocardial infarction No major ventricular arrhythmia Left ventricular ejection fraction least 45 % MUGA Pulmonary : No severe symptomatic restrictive obstructive lung disease FEV_1 great 50 % predict DLCO great 50 % predict Neurologic : No severe central peripheral neurologic abnormality Other : Must HLAA , B , C , D/DR identical sibling age 4 65 , good health No insulindependent diabetes mellitus No major thyroid major adrenal dysfunction No active infection No active malignancy Not pregnant HIV negative HTLVI HTLVII negative PRIOR CONCURRENT THERAPY : Biologic therapy : No excessive anthracycline exposure , unless endomyocardial biopsy show less grade 2 drug effect cardiac scan show least 50 % ejection fraction At least 1 year since prior autologous bone marrow peripheral blood progenitor cell transplant allogeneic bone marrow transplant Chemotherapy : At least 3 week since prior chemotherapy No prior excessive carmustine bleomycin Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy Surgery : Not specify Other : No concurrent nitroglycerin angina pectoris No concurrent antiarrhythmic drug major ventricular dysrhythmias</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>